Clinical Significance of Extrachromosomal DNA in -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience.
作者信息
Aoki Yu, Hashimoto Tadayoshi, Takahashi Nobuyuki, Okunaka Mashiro, Mishima Saori, Kotani Daisuke, Kawazoe Akihito, Nakamura Yoshiaki, Nakayama Izuma, Kuboki Yasutoshi, Bando Hideaki, Kojima Takashi, Nakamura Nobuyuki, Sakamoto Naoya, Ishii Genichiro, Fujisawa Takao, Yoshino Takayuki, Arai Yasuhito, Shibata Tatsuhiro, Shitara Kohei
机构信息
Department of Medical Oncology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
出版信息
JCO Precis Oncol. 2025 Aug;9:e2500033. doi: 10.1200/PO-25-00033. Epub 2025 Aug 18.
Abstract
摘要
相似文献
1
Clinical Significance of Extrachromosomal DNA in -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience.
JCO Precis Oncol. 2025 Aug;9:e2500033. doi: 10.1200/PO-25-00033. Epub 2025 Aug 18.
2
FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.
J Cancer Res Clin Oncol. 2023 Jul;149(8):5289-5300. doi: 10.1007/s00432-022-04460-w. Epub 2022 Nov 23.
3
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Cancer Res. 2008 Apr 1;68(7):2340-8. doi: 10.1158/0008-5472.CAN-07-5229.
4
Circulating Tumor DNA Analysis Detects Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
Clin Cancer Res. 2021 Oct 15;27(20):5619-5627. doi: 10.1158/1078-0432.CCR-21-1414. Epub 2021 Aug 10.
5
Therapeutic potential of calcitriol in cerebral ischemia/reperfusion injury: In vivo and in silico insights into TLR4 and FGFR2 pathways.
IBRO Neurosci Rep. 2025 Jul 29;19:345-353. doi: 10.1016/j.ibneur.2025.06.018. eCollection 2025 Dec.
6
Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers.
Cancer Discov. 2025 Aug 7:OF1-OF24. doi: 10.1158/2159-8290.CD-24-1738.
7
Extrachromosomal DNA Dynamics Contribute to Intratumoral Receptor Tyrosine Kinase Genetic Heterogeneity and Drug Resistance in Gastric Cancer.
Mol Cancer Res. 2025 Jun 3;23(6):503-514. doi: 10.1158/1541-7786.MCR-24-0741.
8
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788.
9
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Clin Cancer Res. 2013 May 1;19(9):2572-83. doi: 10.1158/1078-0432.CCR-12-3898. Epub 2013 Mar 14.
10
The possible role of epigenetics in the etiology of hypospadias.
J Pediatr Urol. 2024 Oct;20(5):877-883. doi: 10.1016/j.jpurol.2024.07.001. Epub 2024 Jul 10.
本文引用的文献
1
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.
Eur J Cancer. 2025 Mar 11;218:115262. doi: 10.1016/j.ejca.2025.115262. Epub 2025 Jan 27.
2
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.
Ann Oncol. 2025 Apr;36(4):426-443. doi: 10.1016/j.annonc.2024.12.011. Epub 2024 Dec 18.
3
Enhancing transcription-replication conflict targets ecDNA-positive cancers.
Nature. 2024 Nov;635(8037):210-218. doi: 10.1038/s41586-024-07802-5. Epub 2024 Nov 6.
4
Origins and impact of extrachromosomal DNA.
Nature. 2024 Nov;635(8037):193-200. doi: 10.1038/s41586-024-08107-3. Epub 2024 Nov 6.
5
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.
Cancer Discov. 2024 Nov 1;14(11):2243-2261. doi: 10.1158/2159-8290.CD-24-0206.
6
Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer.
Biomedicines. 2024 May 17;12(5):1117. doi: 10.3390/biomedicines12051117.
7
Insight on ecDNA-mediated tumorigenesis and drug resistance.
Heliyon. 2024 Mar 11;10(6):e27733. doi: 10.1016/j.heliyon.2024.e27733. eCollection 2024 Mar 30.
8
Oncogenic structural aberration landscape in gastric cancer genomes.
Nat Commun. 2023 Jun 22;14(1):3688. doi: 10.1038/s41467-023-39263-1.
9
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.
10
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
Cancer Sci. 2023 Feb;114(2):574-585. doi: 10.1111/cas.15486. Epub 2022 Dec 4.
Zotero 插件